“…We believe, on the basis of our own experience and of reports from the literature (Liesveld & Abboud, 1991;Malbrain et al, 1994;Zabel & Schlaak, 1991) that in those selected patients CSA can have a role, because it acts to suppress the activation of T lymphocytes and to decrease the output of regulatory cytokines that stimulate eosinophil production from these lymphocytes (Liesveld & Abboud, 1991). Table III lists the chromosomal abnormalities that have been previously reported in association with HES or eosinophilic leukaemia (Baumgarten et al, 1989;Bitran et al, 1977;Broustet et al, 1986;Cabrol, 1979;Chan et al, 1994;Da Silva et al, 1988;Ellman et al, 1979;Fischkoff et al, 1988;Goffman et al, 1983;Goh et al, 1985;Goldman et al, 1975;Guitard et al, 1994;Huang et al, 1979;Humphrey et al, 1981;Kaneko et al, 1983;Keene et al, 1987;Lönnqvist et al, 1979;Maeda et al, 1985;Michel et al, 1991;Mitelman et al, 1975;Needleman et al, 1990;Parreira et al, 1986;Ribeiro et al, 1993;Stockdill et al, 1980;Tono-oka et al, 1984;Weinfeld et al, 1977;Wolz et al, 1993;Yoo et al, 1984). Trisomy 8 is a common finding in myeloid haematological malignancies and has been reported in association with eosinophilic leukaemia or HES in six cases (Bitran et al, 1977;Goh et al, 1985;…”